Exelixis fell after STELLAR-303 failed to achieve statistical significance in overall survival for a key colorectal cancer subgroup, increasing uncertainty around a potential approval path. The result is a material setback for the drug's regulatory outlook and could pressure near-term expectations for the program.
Exelixis fell after STELLAR-303 failed to achieve statistical significance in overall survival for a key colorectal cancer subgroup, increasing uncertainty around a potential approval path. The result is a material setback for the drug's regulatory outlook and could pressure near-term expectations for the program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
